Skip to main content
Skip to footer
Home
About us
Our Business
Strategy and business model
Management
Board of Directors
Contact us
Pipeline
Our Science
Pipeline overview
Projects
Rugocrixan
Fosrugocrixan
Business Development
IP
Publications
Therapeutic areas
Myocardial infarction
Ovarian cancer
Investors
Presentations
Press Releases
Financial Reports
Financial Calendar
Events
The Share
Sustainability
Corporate Governance
Articles of Association
Annual General Meeting
Board Committee
Board
CEO and Management
Auditors
Certified Adviser
Home
About us
Our Business
Strategy and business model
Management
Board of Directors
Contact us
Pipeline
Our Science
Pipeline overview
Projects
Rugocrixan
Fosrugocrixan
Business Development
IP
Publications
Therapeutic areas
Myocardial infarction
Ovarian cancer
Investors
Presentations
Press Releases
Financial Reports
Financial Calendar
Events
The Share
Sustainability
Corporate Governance
Articles of Association
Annual General Meeting
Board Committee
Board
CEO and Management
Auditors
Certified Adviser
Start
>
News
>
English
English
Kancera provides operational update of the Fractalkine and ROR projects
Interim Report for Kancera AB (publ) Q1 2016, January 1 – March 31, 2016
Kancera acquires the Fractalkine project
Kancera provides operational update of the ROR and PFKFB3 projects
Kancera provides operational update of the ROR and Fractalkine projects
Interim Report for Kancera AB (publ) Q4 2015, January 1 – December 31, 2015
Kancera provides operational update of the small molecule patent portfolio
Kancera provides operational update
Interim Report for Kancera AB (publ) Q3 2015. January 1 – September 30, 2015.
Kancera provides operational update on the ROR and Fractalkine projects
